But the organization said the GLP-1 change was not a major reason for the change in results
Those included: Nausea (about 29 to 42 percent of participants, depending on the dose) Diarrhea (25 to 34 percent) Constipation (24 to 26 percent) Vomiting (11 to 25 percent) Upper respiratory tract infection (12 to 14 percent) Interestingly, more people taking a placebo dropped out of the trial because of side effects than participants taking the lowest dose of retatrutide (4.9 percent compared with 4.1 percent)
Try to focus on foods rich in nutrients, limit sugary and high fat foods, and listen to your bodys signals of fullness to make more nutritious dietary choices
Common Adverse Events The most common adverse events in Phase 2 trials were gastrointestinal in nature, reflecting the class effects of GLP-1 receptor activation on gastric motility and central appetite pathways
BY FORMAT The GLP-1 agonists market is segmented by format into single-dose, multi-dose, and tablet forms
The images are either AI-generated or pulled from stock photo libraries
